Quotes

FG001 again showed that it lightens up human brain cancer and an optimal dose giving a high visibility and contrast to the background has been now been determined as an important information for designing the forthcoming clinical study
Morten Albrechtsen, CEO of FluoGuide
Yet another equipment for NIR imaging was used used together with FG001 in this study compared to the data presented yesterday on FG001 guided surgical resection of metastatic pancreatic cancer. This illustrates the important fact that FG001 is compatible with a broad range of types of equipment.
Morten Albrechtsen, CEO of FluoGuide
Translated to humans, this result indicates that half of the patients undergoing traditional white light surgery would have been sent home with a metastasis that could have been detected and removed using FG001
Morten Albrechtsen, CEO of FluoGuide
We are very excited to bring this promising product forward with the potential to help improve the surgical outcome for patients with pancreatic cancer
Morten Albrechtsen, CEO of FluoGuide
We are very pleased with the successful IPO and to see that the potential of uPAR as target for guiding cancer surgery is unfolding earlier than expected as exemplified with the two presentations at WMIC
Morten Albrechtsen, CEO of FluoGuide:
I am very pleased that promising data on the benefit of FG001 in glioblastoma and pancreatic cancer have been selected for presentation at WMIC, an important society within molecular imaging and surgical guidance. Optical targeting of uPAR is likely to become of benefit to patients and surgeons in several cancer indications and this presentation is an important event to highlight the technology’s potential.
Andreas Kjær, responsible for research of FluoGuide:
We are very happy that this promising data has been selected for presentation at WMIC, an important society within molecular imaging and surgical guidance. Optical targeting of uPAR is likely to become of benefit to patients and surgeons in several cancer indications and this presentation is an important event to highlight the technology’s potential.
Andreas Kjær, in charge of research at FluoGuide
We are positive that presentation of the data will contribute to the understanding that uPAR is a highly interesting target and can lead FluoGuide to a leading position in the field of guiding cancer surgery
Morten Albrechtsen, CEO of FluoGuide
We are happy to see another series of promising data now obtained with a product that has been produced under higher quality standards and closer to what will be used in the clinical trial in patients scheduled for next year. This will be an important milestone for the team that has been working hard on FG001 for years
Andreas Kjær, in charge of research at FluoGuide
I am very pleased that we are now more than 1,000 shareholders working together to transform cancer surgery by lighting up the cancer for the benefit of patients and society in general. We have initiated the critical development activities needed for announcing the first clinical result for FG001 in second half of 2020 as planned.
Morten Albrechtsen, CEO FluoGuide A/S
I am very pleased that we are now approx. 1,500 shareholders working together to increase the precision in cancer surgery to the benefit of patients and society in general. We value the trust that we have been shown and we will work hard on delivering on the milestones advancing our first product FG001 towards the market and broad clinical use
Morten Albrechtsen, CEO of FluoGuide
We have seen a strong and broad interest and we’ve boarded our first institutional investor, which is a Danish institutional investor under the regulation of Danish Finanstilsynet, who has become shareholder with a long-term interest. This is very important for FluoGuide and the company’s shareholders
Morten Albrechtsen, CEO of FluoGuide